Shaping Antimalarials: A Geometry-First Approach to Pf CLK3 Covalent Inhibitors
Journal of Medicinal Chemistry · 2026
DOI: 10.1021/acs.jmedchem.5c03342 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Skye B Brettell und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry, The Advanced Research Centre, University of Glasgow, 11 Chapel Lane, Glasgow G11 6EW, U.K. Hauptthemen laut MEDLINE: Antimalarials, Plasmodium falciparum, Protein Kinase Inhibitors, Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Engineering and Physical Sciences Research Council, Biotechnology and Biological Sciences Research Council.
Abstract (Originalsprache)
The emergence ofPlasmodium falciparumresistance to frontline therapies highlights the urgent need for new antimalarial agents. The essential, multistage kinase PfCLK3 is a validated target, and covalent kinase inhibitors (CKIs) offer potential for durable inhibition. However, CKI design has largely prioritised warhead reactivity over the geometric requirements which govern covalent bond formation. Herein, we describe a geometry-first approach to optimize covalent PfCLK3 inhibitors, starting from the highly reactive chloroacetamide SB4-17 (2). Systematic variation of warhead and linker geometry revealed that maintaining the α-reactive geometry of the chloroacetamide scaffold enables covalent engagement of Cys368 with substantially less reactive electrophiles. Notably, the methyl sulfamate analogue SB5-171 (14) showed potent antiparasitic activity (EC50 = 104 nM) and improved metabolic stability (t1/2 = 35 min in mouse hepatocytes). These findings demonstrate that geometric optimization can decouple covalent engagement from high intrinsic reactivity, providing a rational framework for designing selective, drug-like CKIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Chemistry, The Advanced Research Centre, University of Glasgow, 11 Chapel Lane, Glasgow G11 6EW, U.K.
- Keltic Pharma Therapeutics, The Advanced Research Centre, University of Glasgow, 11 Chapel Lane, Glasgow G11 6EW, U.K.
- Centre for Translational Pharmacology, The Advanced Research Centre, University of Glasgow, 11 Chapel Lane, Glasgow G11 6EW, U.K.
- EaSTCHEM School of Chemistry, University of Edinburgh, Joseph Black Building, David, Brewster Road, Edinburgh EH9 3FJ, U.K.
ORCID-Profile: Skye B Brettell, Graeme Milligan, David J Clarke, Andrew B Tobin, Andrew G Jamieson
Förderung
- Engineering and Physical Sciences Research Council
- Biotechnology and Biological Sciences Research Council
Zitieren
APA
Brettell, S. B., Fuentes-Guerra Bustos, C., Sharma, S., Cann, G., Carruthers, L. V., Begen, A., Milligan, G., Clarke, D. J., Tobin, A. B., & Jamieson, A. G. (2026). Shaping Antimalarials: A Geometry-First Approach to Pf CLK3 Covalent Inhibitors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c03342
Vancouver
Brettell SB, Fuentes-Guerra Bustos C, Sharma S, Cann G, Carruthers LV, Begen A, et al. Shaping Antimalarials: A Geometry-First Approach to Pf CLK3 Covalent Inhibitors. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.5c03342
BibTeX
@article{Brettell2026,
author = {Brettell, Skye B and Fuentes-Guerra Bustos, Carla and Sharma, Saumya and Cann, Gillian and Carruthers, Lauren V and Begen, Abbey and Milligan, Graeme and Clarke, David J and Tobin, Andrew B and Jamieson, Andrew G},
title = {Shaping Antimalarials: A Geometry-First Approach to Pf CLK3 Covalent Inhibitors},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.5c03342}
}
EUVIMED